UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Tivozanib for the treatment of renal cell carcinoma: patient selection and perspectives

International journal of nephrology and renovascular disease, 2019-05, Vol.12, p.137-141

2019

Volltextzugriff (PDF)

The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review

European journal of cancer (1990), 2006-12, Vol.42 (18), p.3127-3139

2006

Volltextzugriff (PDF)

Angiogenesis inhibitors in clinical development; where are we now and where are we going?

British journal of cancer, 2004-01, Vol.90 (1), p.1-7

ESKENS, Falm

2004

Volltextzugriff (PDF)

Angiogenesis inhibitors in clinical development; where are we now and where are we going?

British journal of cancer, 2004-01, Vol.90 (1), p.1-7

Eskens, F A L M

2004

Volltextzugriff (PDF)

The spliceosome as target for anticancer treatment

British journal of cancer, 2009-01, Vol.100 (2), p.228-232

2009

Volltextzugriff (PDF)

Differentiation and Definition of Vascular-Targeted Therapies

Clinical cancer research, 2005-01, Vol.11 (2), p.416-420

2005

Volltextzugriff (PDF)

Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours

European Journal of Cancer, 2009-07, Vol.45 (10), p.1764-1772

2009

Volltextzugriff (PDF)

Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules

Cancer chemotherapy and pharmacology, 2015-02, Vol.75 (2), p.365-371

2015

Volltextzugriff (PDF)

Matrix Metalloproteinase Inhibitors: Current Developments and Future Perspectives

The oncologist (Dayton, Ohio), 2001-10, Vol.6 (5), p.415-427

2001

Volltextzugriff (PDF)

Influence of OATP1B1 Function on the Disposition of Sorafenib‐β‐D‐Glucuronide

Clinical and translational science, 2017-07, Vol.10 (4), p.271-279

2017

Volltextzugriff (PDF)

A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours

British journal of cancer, 2010-10, Vol.103 (9), p.1362-1368

2010

Volltextzugriff (PDF)

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Thrombospondin-1–Mimetic Angiogenesis Inhibitor ABT-510 in Patients With Advanced Cancer

Journal of clinical oncology, 2005-08, Vol.23 (22), p.5188-5197

2005

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of DE-310 in Patients with Advanced Solid Tumors

Clinical cancer research, 2005-01, Vol.11 (2), p.703-711

2005

Volltextzugriff (PDF)

Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours

British journal of cancer, 2010-09, Vol.103 (7), p.987-992

2010

Volltextzugriff (PDF)

Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy

British journal of cancer, 2003-12, Vol.89 (11), p.2045-2050

2003

Volltextzugriff (PDF)

A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors

Annals of oncology, 2006-08, Vol.17 (8), p.1320-1327

2006

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of the Oral Farnesyl Transferase Inhibitor SCH 66336 Given Twice Daily to Patients With Advanced Solid Tumors

Journal of clinical oncology, 2001-02, Vol.19 (4), p.1167-1175

2001

Volltextzugriff (PDF)

Phase I and Pharmacological Study of the Oral Matrix Metalloproteinase Inhibitor, MMI270 (CGS27023A), in Patients with Advanced Solid Cancer

Clinical cancer research, 2001-07, Vol.7 (7), p.1912-1922

2001

Volltextzugriff (PDF)

Phase I and Pharmacologic Study of PKI166, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Advanced Solid Malignancies

Clinical cancer research, 2005-10, Vol.11 (19), p.6908-6915

2005

Volltextzugriff (PDF)

Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: A safe combination

European journal of cancer (1990), 2006-03, Vol.42 (4), p.467-472

2006

Volltextzugriff (PDF)

Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer

British journal of cancer, 2002-03, Vol.86 (5), p.669-673

2002

Volltextzugriff (PDF)

Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours

European journal of cancer (1990), 2002-11, Vol.38 (17), p.2272-2278

2002

Volltextzugriff (PDF)

Temozolomide chemotherapy in recurrent oligodendroglioma

Neurology, 2001-07, Vol.57 (2), p.340-342

2001

Volltextzugriff (PDF)

Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933

European journal of cancer (1990), 2002-05, Vol.38 (8), p.1090-1099

2002

Volltextzugriff (PDF)

A Phase I and Pharmacokinetic Study of Weekly Paclitaxel and Carboplatin in Patients with Metastatic Esophageal Cancer

Clinical cancer research, 2004-03, Vol.10 (6), p.1928-1934

2004

Volltextzugriff (PDF)

1 – 25 von 39

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(37)

Publikationsform

Artikel
(39)

Sprache

Englisch
(39)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(38)
Science & Technology
(38)
Humans
(35)
Oncology
(33)
Biological And Medical Sciences
(27)
Medical Sciences
(27)
Middle Aged
(25)
Female
(24)
Male
(23)
Aged
(22)
Adult
(20)
Neoplasms - Drug Therapy
(19)
Pharmacology. Drug Treatments
(19)
Antineoplastic Agents
(17)
Tumors
(14)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(13)
Dose-Response Relationship, Drug
(10)
Chemotherapy
(9)
Phase I
(9)
Infusions, Intravenous
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Tivozanib for the treatment of renal cell carcinoma: patient selection and perspectives

The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review

Angiogenesis inhibitors in clinical development; where are we now and where are we going?

Angiogenesis inhibitors in clinical development; where are we now and where are we going?

The spliceosome as target for anticancer treatment

Differentiation and Definition of Vascular-Targeted Therapies

Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours

Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules

Matrix Metalloproteinase Inhibitors: Current Developments and Future Perspectives

Influence of OATP1B1 Function on the Disposition of Sorafenib‐β‐D‐Glucuronide

A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Thrombospondin-1–Mimetic Angiogenesis Inhibitor ABT-510 in Patients With Advanced Cancer

Phase I and Pharmacokinetic Study of DE-310 in Patients with Advanced Solid Tumors

Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours

Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy

A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors

Phase I and Pharmacokinetic Study of the Oral Farnesyl Transferase Inhibitor SCH 66336 Given Twice Daily to Patients With Advanced Solid Tumors

Phase I and Pharmacological Study of the Oral Matrix Metalloproteinase Inhibitor, MMI270 (CGS27023A), in Patients with Advanced Solid Cancer

Phase I and Pharmacologic Study of PKI166, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Advanced Solid Malignancies

Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: A safe combination

Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer

Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours

Temozolomide chemotherapy in recurrent oligodendroglioma

Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933

A Phase I and Pharmacokinetic Study of Weekly Paclitaxel and Carboplatin in Patients with Metastatic Esophageal Cancer

Suchergebnisse filtern